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Débora Balabram1, Cassio M Turra2 and Helenice Gobbi1*Abstract
Background: Breast cancer incidence is increasing. The survival rate varies and is longer in high-income countries.
In Brazil, lower-income populations rely on the Unified Public Health System (Sistema Único de Saude, SUS) for
breast cancer care. The goal of our study is to evaluate the survival of patients with operable breast cancer stages
I-III at a Brazilian public hospital that treats mostly patients from the SUS.
Methods: A cohort study of patients who underwent surgery for breast cancer treatment at the Clinical Hospital of
the Federal University of Minas Gerais from 2001 to 2008 was performed, with a population of 897 cases.
Information on tumor pathology and staging, as well as patients’ age and type of health coverage (SUS or private
system) was collected. A probabilistic record linkage was performed with the database of the Mortality Information
System to identify patients who died by December 31th, 2011. The basic cause of death was retrieved, and breast
cancer-specific survival rates were estimated with the Kaplan-Meier method. The Cox proportional hazards model
was used for univariate and multivariate analysis of factors related to survival.
Results: A total of 282 deaths occurred during the study’s period, 228 of them due to breast cancer. Five-year
breast cancer-specific survival rates were 95.5% for stage I, 85.1% for stage II and 62.1% for stage III disease. Patients
from the SUS had higher stages at diagnosis (42% was in stage III, and from the private system only 17.6% was in
this stage), and in the univariate but not multivariate analysis, being treated by the SUS was associated with shorter
survival (hazard ratio, HR = 2.22, 95% CI 1.24-3.98). In the multivariate analysis, larger tumor size, higher histologic
grade, higher number of positive nodes and age older than 70 years were associated with a shorter breast cancer-
specific survival.
Conclusions: Five-year breast cancer survival was comparable to other Brazilian cohorts. Patients treated by the
SUS, rather than by the private system, had shorter survival times, mostly due to higher initial stage of the disease.
Keywords: Breast neoplasms, Survival analysis, Neoplasm staging, Brazil, Cohort studyBackground
Breast cancer is the most common malignant neoplasm
among women in the world. The incidence is increasing,
especially in low and middle-income countries [1]. In
2012, the incidence of breast cancer was expected to be
52.5 per 100,000 women in Brazil [2], whereas the age-
adjusted mortality was 11.5 deaths per 100,000 women
in 2009 [3]. In high-income regions, population-based* Correspondence: hgobbi@medicina.ufmg.br
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reproduction in any medium, provided the orstudies show higher survival rates [4]: for patients diag-
nosed between 1990 and 1994, 5-year relative survival
was 83.9% in the United States (US) and 73.1% in
Europe [4]. In low-income countries, shorter overall sur-
vival has been documented, being as low as 38.8% in
Sétif, Algeria, for patients diagnosed in the same period
[4]. In Goiania, located in the central-west region of
Brazil, the survival rate was 65.4% [4].
A patient’s survival is related to several prognostic fac-
tors, including number of positive lymph nodes, tumor
size, hormone receptor status, histological type and
grade, and patient’s age [5]. Socioeconomic status isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of lower frequencies of patients undergoing interval
screening, treatment’s delay and smaller availability of
modalities of treatment, such as chemo, hormone, and
radiotherapy, among the less affluent populations [6-9].
In Brazil, most of the population does not have private
health insurance, and relies on the Unified Public Health
System (Sistema Único de Saúde, SUS) for care, which
provides patients with screening, diagnosis, and breast
cancer treatment [10,11]. In 2008, only 26% of the
Brazilian population had private health insurance [11].
Studies from Brazil and other countries were retrieved
from the PubMed and LILACS databases in February 14,
2013, using the search terms breast cancer, survival, and
Brazil. Seven hospital cohort studies that separated pa-
tients by stage and were not aiming to evaluate specific
prognostic markers or new treatments were selected. For
PubMed, English language was used, and for LILACS,
both the English and Portuguese languages were used.
Findings from these observational cohorts in different
Brazilian hospitals suggested that 5-year breast cancer-
specific survival rates have ranged from 90% to 97% for
stage I, 87.8% to 89% for stage II and 51% to 73% for stage
III breast cancer diagnosed since the 1990s [6,12-16]. In
these studies, the methods used to classify a death as due
to breast cancer or its treatment vary, and they are some-
times poorly reported or derived only from the basic cause
of death, as reported in patients’ death certificates.
In this article, we present new estimates of survival for
Brazilian female patients with operable breast carcinoma
(stages I-III). We provide estimates for both overall survival
rates and breast cancer-specific survival rates, calculated as
the probability of surviving breast cancer in the absence of
other causes of death [17]. We also look at the association
between several prognostic markers and survival rates. Our
data come from patients treated from 2001 to 2008 at the
Clinical Hospital of the Federal University of Minas Gerais
(Hospital das Clínicas, Universidade Federal de Minas
Gerais, HC-UFMG), Belo Horizonte, Brazil. The HC-
UFMG is a general teaching hospital that treats mostly
patients from the SUS coming from Belo Horizonte (the
state’s capital) or from smaller cities without a tertiary
health care center [18]. It provides patients with surgery as
well as chemo- and endocrine therapies. Radiotherapy is
performed at other cancer centers in the city. The Breast
Pathology Laboratory of the UFMG School of Medicine is
responsible for all breast pathology exams from the HC-
UFMG and it has kept records of diagnostic and surgical
specimens from it since 1989 [18].
Methods
Study’s design
We designed a cohort study of patients with invasive op-
erable breast carcinoma in stages I-III surgically treatedat HC-UFMG from 2001 to 2008. The study protocol was
approved by the UFMG Ethics Committee on March 7,
2012 (project CAAE number 0660.0.203.000-11).
Study’s population
The cases were retrieved from files of the Breast Path-
ology Laboratory of the UFMG School of Medicine. We
selected all specimens related to surgical treatment of
breast cancer.
Among the 1119 patients who underwent surgery for
breast cancer treatment at HC-UFMG from 2001 to
2008, we excluded 166 cases of ductal and lobular
carcinoma in situ, as well as 2 patients with axillary me-
tastasis only (unknown primary site), 1 patient with un-
known tumor stage, 27 patients with unavailable
primary tumor sample at our institution (first surgery at
another institution, no remaining tumor in re-excision
for clear margins), 7 patients with metastatic breast can-
cer who underwent palliative surgery only, 14 patients
who underwent surgery for recurrent breast cancer, 1
patient who moved to a different state while on treat-
ment and 4 patients with missing date of birth and
mother’s name. Eight hundred ninety-seven cases were
available for the final analysis.
Variables
In addition to date of birth and type of health plan (pri-
vate insurance or SUS), we recorded twelve variables
related to breast cancer diagnosis and treatment: pa-
tient’s age, tumor size (T), regional lymph node status
(N), age, laterality (right or left), having bilateral cancer,
histopathological type (invasive ductal carcinoma not
otherwise specified; invasive lobular carcinoma; and
special-type carcinomas), histologic tumor grade (accor-
ding to the Nottingham grading system) [5], type of
surgery performed (mastectomy or breast-conserving
surgery), undergoing axillary node dissection, use of
neoadjuvant chemo- or hormone therapy, and type of
health plan (SUS or private system) [11]. Tumor staging
was performed in accordance with the 7th edition of the
American Joint Committee on Cancer (AJCC) Cancer
Staging Manual [5]. For patients who did not undergo
neoadjuvant systemic therapies, pathologic tumor stage
(which is the gold standard for cancer staging) was used
[5]; in the other cases, clinical tumor stage prior to ther-
apy was used as a surrogate.
Information on survival status and death causes
We retrieved information on survival status, and date
and cause of death from the Mortality Information Sys-
tem (MIS) of the Ministry of Health in Brazil for the
years 2001 through 2011. The MIS is a national, com-
puterized index of death record information that was
implemented in 1975. Over the years, the completeness
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tially, reaching 93.5% as of 2007 in Minas Gerais [19].
Because patients from the HC-UFMG were all residents
of the state of Minas Gerais, we restricted the MIS
database to the cases who were residing in Minas Gerais
at the date of their death. To identify patients from
the study cohort who died from January 1, 2001 to
December 31, 2011, we linked the MIS death records to
the HC-UFMG data. A probabilistic record linkage was
conducted using the software RecLink, version 3.0
(http://www.iesc.ufrj.br/reclink/) [20]. The probabilistic
method is used when a unique identifier, such as social
security number, is unavailable. To reduce the number
of possible pairs, after standardizing both databases, we
applied a four-step blocking strategy: first, using the
soundex code of patients’ first and last names and years
of birth; second, using the soundex code of the mothers’
first and last names and years of birth; third, based on
soundex code of patients’ and mothers’ first name and
years of birth; and fourth with only patients’ first names
and years of birth. We then paired the cases within each
block, and estimated a linkage score for each pair based
on the name and date of birth. All pairs with scores
higher than 1 were reviewed in order to confirm them
as true or false by using the fathers’ names and ad-
dresses. Patients who were not found in the MIS data-
base were presumed to be alive as of December 31, 2011
and therefore censored at this date.
In the Mortality Information System, causes of death
are classified according to the International Classifica-
tion of Diseases, version 10 (ICD 10) [21], by a techni-
cian [22].
After reading all causes of death described in each
death certificate, we applied the coding by the Surveil-
lance, Epidemiology, and End Results (SEER), of the U.S.
National Cancer Institute to estimate breast cancer-
specific survival. Cases with unknown death causes were
not excluded [17]. When the cause of death was un-
known or the patient died without assistance (8 cases,
2.8%), breast cancer was considered to be the cause [23].
When breast cancer was considered to have contributed
to death, the patient was classified as having died from
the disease (12 cases, 4.3%) [9].
An alternative analysis was performed, considering
only the basic cause of death, as selected by technicians
from the State’s Secretaries in Health, which is used for
national mortality statistics. The methods reported by
SEER were also used in this situation.
Statistical analysis
We estimated Kaplan-Meier curves to describe the sur-
vival of this cohort over 5- and 10-year periods. We used
the log-rank test to compare the survival distributions of
different subgroups in our data. Since the date of thefirst biopsy was not available for all patients who had
surgery as the primary treatment, survival interval was
calculated in months from date of surgery in patients
who did not undergo neoadjuvant chemo- or hormone
therapy and from biopsy date in patients who underwent
such therapies. Also, we tried to keep the staging as ac-
curate as possible by using the clinical stage at the date
of biopsy or the pathological stage at the date of surgery.
Age was categorized in three subgroups: up to 35
years, 36–69 years, and 70 years and older.
Mean age and standard deviation (SD) were calculated.
The chi-square test was used to compare categorical var-
iables. The chi-square test for a linear trend was used to
compare the frequencies of tumor stage over the years
of the study, as well as tumor stage in each age category.
The significance level was defined as 0.05. The Cox pro-
portional hazards model was used for hazard ratio (HR)
and 95% confidence interval (CI) estimation in the uni-
variate analysis and for multivariate survival analysis
with a stepwise backward conditional strategy. Variables
with statistical significance (p < 0.05) in the univariate
analysis were initially used for the multivariate model,
except for type of surgery, performing axillary node dis-
section, and use of neoadjuvant therapy, since we had
incomplete data on treatment, to avoid biasing the re-
sults. For instance, patients diagnosed at higher stages
probably underwent adjuvant systemic therapies later
on. However, we did not have the data to confirm this
information. Only variables with a p value bellow 0.05
were kept in the final multivariate model. All statistical
analyses were performed with the SPSS software, version
17.0 (SPSS Inc, Chicago, IL).
Results
Five-year breast cancer-specific survival for the entire
cohort was 78.5%, and 10-year survival was 64.5%. The
cause-specific survival was 95.5% at 5 years for stage I,
85.1% for stage II, and 62.1% for stage III disease. Over-
all survival was 92.1% for stage I, 81.8% for stage II, and
58% for stage III disease. Only a small proportion of our
patients were followed over a 10-year period (45 pa-
tients, 5%); among those in stage I, 10-year survival rate
was 91.2%, 69.8% for stage II, and 43% for stage III
patients.
The median period of follow-up was 64 months (range
1–131 months). Among the 897 patients, 282 (31.44%)
died during follow-up, out of whom 228 (80.9%) died
from breast cancer and 54 (19.1%) from other causes.
Cardiovascular diseases (ICD 10 chapter IX) was a fre-
quent cause of death unrelated to breast cancer, with 16
cases (29.6% of other death causes, data not shown).
Four patients had unattended deaths (1.42% of total of
deaths), and 3 patients (1.06% of total of deaths) had
deaths from unknown causes.
Table 1 Patients’ characteristics and univariate analysis of factors related to survival
Factor Cases % Events % p value* HR 95% CI**
Age .012
Up to 35 years old 47 5.24 16 34.04 1.63 0.98–2.73
36-69 years old 677 75.47 159 23.49 1.00
70 and older 173 19.29 53 30.64 1.50 1.10–2.04
Tumor size < 0.001
T1 (up to 2 cm) 319 35.56 33 10.34 1.00
T2 (2–5 cm) 348 38.80 88 25.29 2.59 1.73–3.86
T3 105 11.71 37 35.24 4.03 2.52–6.45
T4 125 13.94 70 56.00 8.02 5.29–12.16
Lymph node status < 0.001
N0 387 43.14 45 11.63 1.00
N1 255 28.43 67 26.27 2.56 1.76–3.74
N2 155 17.28 68 43.87 4.83 3.31–7.04
N3 100 11.15 48 48.00 5.25 3.50–7.90
Stage < 0.001
I 223 24.86 13 5.83 1.00
II 315 35.12 58 18.41 3.34 1.83–6.10
III 359 40.02 157 43.73 9.84 5.58–17.33
Bilateral breast cancer 0.380
Yes 29 3.23 10 34.48 1.33 0.70–2.50
No 868 96.77 218 25.12 1.00
Histologic grade < 0.001
Grade 1 181 20.18 23 12.71 1.00
Grade 2 385 42.92 77 20.00 1.71 1.07–2.72
Grade 3 320 35.67 124 38.75 3.72 2.38–5.80
Unknown 11 1.23 4 36.36
Pathology 0.00 .449
Invasive ductal carcinoma 760 84.73 199 26.18 1.00
Invasive lobular carcinoma 79 8.81 15 18.99 0.73 0.43–1.23
Other 58 6.47 14 24.14 0.86 0.50–1.48
Public health system 0.006
Yes 823 91.75 216 26.25 2.22 1.24–3.98
No 74 8.25 12 16.22 1.00
Neoadjuvant therapy <0.001
Yes 166 18.51 77 46.39 2.87 2.18–3.78
No 731 81.49 151 20.66 1.00
Axillary node dissection <0.001
Yes 684 76.25 211 30.85 3.82 2.33–6.27
No 213 23.75 17 7.98 1.00
Type of surgery <0.001
Mastectomy 537 59.87 182 33.89 2.89 2.09–4.00
Breast-conserving surgery 360 40.13 46 12.78 1.00
*Log-rank test.
**95% Confidence interval.
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tics, life status at the end of the study period, and HR
for the different factors examined in the univariate ana-
lyses. The mean age of patients was 55.32 years (SD =
13.97, range 20–97 years), and the median age was 53
years. Only 47 patients (5.24%) were 35 years old or
younger; 677 patients (75.47%) were between 36 and 69
years, and 173 patients (19.29%) were 70 and older.
Most individuals (823, 91.75%) were treated in the SUS;
only 74 (8.25%) were treated in the private health sys-
tem. Of those, 65 had private insurance and 9 paid for
their treatment. Three hundred forty-eight patients had
T2 tumors (2 to 5 cm, 38.8%). As for the axilla, 387 pa-
tients (43.14%) had negative lymph nodes, while 510 pa-
tients (56.86%) had at least one positive node. A great
number of patients were in stage III at diagnosis (359
cases, 40.02%). Twenty-nine patients had bilateral breast
cancer either concomitantly or at follow-up, that was
treated at our institution (3.23%). Left breast tumors
were more common (472 patients, 52.6%). Regarding
pathologic type, most patients had invasive ductal car-
cinoma not otherwise specified (760, 84.73%). Seventy-
nine patients had invasive lobular carcinoma (8.81%),
and 58 patients (6.47%) had other pathologic subtypes.
One hundred eighty-one patients had low-grade tumors
(20.18%), 385 had intermediate-grade tumors (42.92%)Figure 1 Kaplan-Meier curves of factors associated with breast cance
(p < 0.001). B, survival in relation to lymph node status (p < 0.001). C, surviv
health care system (p = 0.006).and 320 had high-grade tumors (35.67% of patients).
The most common surgery was mastectomy, performed
in 59.87% of patients (537 cases). Axillary node dissec-
tion was performed in 684 (78.25%) patients. One hun-
dred sixty-six patients (18.51%) underwent neoadjuvant
therapies (3 had combined neoadjuvant chemo- and hor-
mone therapy, 4 had hormone therapy exclusively and
the other patients had neoadjuvant chemotherapy only).
The stage at diagnosis was higher among patients from
the SUS (23.1% was stage I, 34.9 stage II and 42% stage
III in the public health system, while 44.6% was stage I,
37.8 was stage II, and 17.6% was stage III in the private
health system, p < 0.001). The frequencies of stages did
not change over the years (p = 0.11, data not shown).
In the univariate analysis, breast cancer in patients
older than 70 years of age was associated with signifi-
cantly lower chances of survival compared to patients 35
to 69 years old. Also, higher histologic tumor grade, lar-
ger tumor size, and higher number of involved lymph
nodes were associated with lower survival (Figure 1,
Table 1). Being treated by the SUS was associated with a
shorter survival, with an HR of 2.22 (p = 0.005, CI 1.24-
3.98). Older age was not associated with a different stage
of disease (p value of Χ2 for a linear trend = 0.22) but
was associated with a smaller proportion of patients
undergoing neoadjuvant systemic therapies (only 8.7% ofr survival. A, breast cancer-specific survival in relation to tumor size
al in relation to histologic grade (p < 0.001). D, survival in relation to
Balabram et al. BMC Cancer 2013, 13:434 Page 6 of 10
http://www.biomedcentral.com/1471-2407/13/434patients older than 70 years underwent such therapies,
whereas 20.8% of patients 36–69 years and 21.3% of pa-
tients up to 35 years of age underwent such treatments,
p = 0.001, data not shown).
Having bilateral breast cancer and having lobular or
special-type carcinomas was not associated with a
shorter survival time. In terms of therapy, undergoing
neoadjuvant systemic therapy, undergoing mastectomy
and undergoing axillary node dissection were associated
with shorter survival time, but these variables are highly
correlated to tumor stage (Table 1).
In the multivariate analysis, tumor size remained an
important prognostic factor. Patients with tumors larger
than 5 cm (T3) had an HR of dying due to breast cancer
of 2.31 (CI 1.41-3.80) compared to patients with tumors
measuring up to 2 cm (T1, Table 2). In addition, patients
with tumors infiltrating the skin or chest wall had an HR
of 4.34 (CI 2.77-6.79) in relation to T1 patients. Patients
with 9 or more positive axillary lymph nodes had an HR
of 3.59 (CI 2.35-5.48) in relation to patients with negative
nodes. Also, patients aged 70 years and older had a shorter
survival (HR in relation to women 36–69 years old, 1.64;
CI 1.19-2.26). Patients with high-grade tumors had an HR
of 2.54 (CI 1.62-3.96) in relation to patients with low-
grade tumors. Being treated by the SUS was not associated
with a shorter survival in multivariate analysis.
When the basic cause of death, as classified by the
state’s technician, was used alone, 25 patients (9.22% of
the total of deaths) would have been censored and notTable 2 Multivariate survival analysis – final model
Factor p value HR 95% CI
Age
Up to 35 0.125 1.50 0.89–2.51
36-69 0.005 1.00
70 and above 0.002 1.64 1.19–2.26
Tumor size
T1 <0.001 1.00
T2 0,027 1.60 1.05–2.43
T3 <0.001 2.31 1.41–3.80
T4 <0.001 4.34 2.77–6.79
Lymph node status
N0 <0.001 1.00
N1 0.005 1.75 1.18–2.60
N2 <0.001 2.73 1.82–4.09
N3 <0.001 3.59 2.35–5.48
Histologic grade
Grade 1 <0.001 1.00
Grade 2 0.313 1.27 0.80–2.01
Grade 3 <0.001 2.54 1.62–3.96
HR hazard ratio, 95% CI 95%, Confidence interval.considered to have died from breast cancer. In such
cases, information contained in the death certificate sug-
gested breast cancer as a contributing cause of death,
and we decided to be conservative and, as done by other
authors, consider the patient as having died from breast
cancer [12]. These patients’ basic causes of death
were: diseases of the circulatory system (7 cases, ICD
chapter IX); endocrine, nutritional and metabolic dis-
eases (3 cases, ICD chapter IV); diseases of the respira-
tory system (2 cases, ICD chapter X); diseases of the
blood and blood-forming organs (1 case, ICD chapter
III), and other neoplasms: unspecified malignant neo-
plasm of the liver (3 patients), unspecified malignant
neoplasm of the bronchus and lung (3 cases), malignant
neoplasm of the cerebellum (1 case, C71.6), malignant
neoplasm of the cervix uteri (1 case, C53.9), malignant
neoplasm of bone and articular cartilage of other and
unspecified sites (1 case, C41.9), Letterer-Siwe disease
(C96.0, 1 case), malignant neoplasm of the brain (1 case,
C71.9), and malignant neoplasm of the mandible (1 case,
C41.4). In those latter cases, the other cancer could have
been the primary cause of death, but it seems more
plausible, except for the patient who had a cervical can-
cer, that they were secondary malignancies.
When patients with deaths that were correctly classi-
fied as due to breast cancer were excluded (203 cases,
72% of total of deaths), higher stage (stage III versus
stages I and II) remained associated with a higher HR
of dying from other causes (HR = 2.02, CI 1.30-3.14,
p = 0.002). After reading other death causes present in
the death certificate and reassigning the basic death
cause, this effect disappeared (p = 0.16).
Discussion
Five-year breast cancer-specific survival for the entire
cohort was 78.5%. Our survival findings are in accord-
ance with earlier studies that were based on different
Brazilian cohorts. The study by Ayala [13] described
5-year survival rates of 97% for stage I, 88% for stage II,
and 51% for stage III in patients treated in the SUS, con-
sidering patients diagnosed at a similar period to the one
of our study (2000–2009). Cintra et al. [14] showed a
5-year breast cancer-specific survival of 90% for stage I,
89% for stage II, and 68.7% for stage III patients from a
mixed sample of the SUS and private systems treated
from 1998 to 2000. Schneider & d’Orsi [12] showed sur-
vival proportions of 93.6% for stage I, 87.8% for stage II,
and 62.5% for stage III patients, also from a mixed sam-
ple, diagnosed between 2000 and 2002. Menke et al. [24]
showed an overall survival (all causes of death) above
80% in Porto Alegre, Rio Grande do Sul, in a study with
patients treated from 1972 to 2002. In this study, the
origin of the sample (SUS or private system) was not
specified. Variations in survival could be due to different
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different sample compositions regarding stage, age, and
other biologic tumor factors, as well as differences in
local cancer care.
For patients diagnosed in the United States in the
years 2001 and 2002 (National Cancer Data Base),
5-year overall survival was 87.8% for stage I, ranged from
74% to 81.4% for stage II (IIB and IIA, respectively) and
from 41% to 66.7% for stage III disease (IIIB and IIIA,
respectively) [5]. In a public hospital in Barcelona, Spain,
5-year breast cancer-specific survival of patients diag-
nosed from 1992 to 2005 was 97.1% for stage I, 88% for
stage II, and 70.1% for stage III patients [25].
Studying breast cancer survival and prognostic factors
gives us insight into the natural history of the disease.
Many prognostic factors have been studied over the
years. The factor with the highest impact on survival is
lymph node invasion (N). Tumor size (T) and distant
metastasis (M) also play an important role, as well as
lymph vascular invasion, positivity for hormone recep-
tors, and over-expression of the HER2 protein [5]. Many
other markers are linked to breast cancer survival [5]. In
spite of the growing number of markers being discov-
ered recently, the TNM remains the most important
predictor of breast cancer survival [5]. In our study,
tumor size and lymph node status were the strongest
predictors of survival.
Socioeconomic status is also an intervening factor
[6-8]. Most patients from our study were treated in the
Brazilian public health system (SUS). Since lower income
patients do not have private health insurance and usually
cannot afford breast cancer treatment, they rely on the
SUS for it. Not having private insurance and thus using
the SUS was considered a surrogate for socio-economic
information. The SUS provides multiple modalities of
treatment for breast cancer patients, such as surgery and
radio- and systemic therapy [10,11]. Our findings sug-
gest that the survival of patients from the SUS is shorter
than from the ones of the private system. Most of this
difference is likely due to the different distribution of
stages at diagnosis. Other contributing factors that were
not analyzed in the present study could also explain this
finding, such as larger interval between diagnosis and
treatment in SUS’ patients [6,14], more difficult access
to health care facilities, different comorbidities, smaller
proportion of women undergoing screening, and a
different lifestyle with other risk factors for death
[8,9,26,27]. To minimize treatment delay, a federal law
that was approved in 2012 stated that after diagnosis,
cancer patients should be treated at an interval no lon-
ger than 60 days in the SUS [28].
The Brazilian SUS also provides breast cancer screen-
ing with mammography according to national guidelines
[29]: since 2004, women aged 50–69 years have beenencouraged to undergo mammography every 2 years,
and also to have their breasts examined by a physician
since 40 years of age. In private practice, guidelines from
the Brazilian Society of Breast Surgery (Sociedade
Brasileira de Mastologia) are followed, with a recom-
mendation to use mammography screening yearly since
40 years of age [30]. In spite of these recommendations,
Marchi and Gurgel [31] showed that women’s adherence
to screening is low, with less than 50% performing bian-
nual exams (24.5% for SUS patients and 42.9% for pa-
tients from the private system from 2003 to 2008).
Another study showed similar results (34.9% adherence
for women aged 50–59 years of the SUS and 71% for
women of the private health system) [32]. Nevertheless,
the use of mammograms is growing, with 54.6% of
women 50 to 69 years of age having undergone at least
one mammogram in their lifetime up to 2003 and 71.5%
up to 2008 [33]. The proportion of women older than 70
years old undergoing mammography is smaller (37.1%
up to 2003 and 54.5% up to 2008) [33]. Lower screening
rates are consistently associated with not having private
insurance and smaller income in many studies [31-34].
With the Brazilian Information System for Breast Cancer
(Sistema de Informação do Câncer de mama - SISMA
MA), implemented by the Brazilian National Cancer
Institute in 2009, the number of women undergoing
screening in the SUS is expected to rise. It will possibly
result in more patients being diagnosed at earlier stages
[29] and better overall survival. In our study, the
frequencies of stages did not change over the years
(P = 0.114, data not shown). It is possible that in the
later years of the study, more patients were diagnosed
with in situ tumors, which has been shown in a previous
publication [18], but these tumors were not the scope of
the present study. Also, our time span was too small to
show any differences.
In our study, patients 70 years old and older had shorter
breast cancer-specific survival. Schonberg et al. [35]
showed a higher mortality for women older than 80 years
in the US, and they argue that these women could have
undergone less-than-standard treatment. This explanation
has been presented by other authors and could have been
the case for our patients [25,36]. Comorbidities can play a
role, as well as smaller proportions of patients undergoing
screening in this population [25,33]. Thus, our results dif-
fer from the findings of Brito et al. [6], which show better
breast-cancer specific survival for patients older than 70
years treated in the SUS between 1999 and 2002 and
shorter for younger patients (at the end of their study,
81.5% of patients older than 70 years were alive, versus
only 45.4% of patients less than 35 and 72% for patients 35
or more and less than 70 years of age) [6]. On the other
hand, older women are more likely to die of a variety of
other causes, mainly cardiovascular diseases [26,37].
Balabram et al. BMC Cancer 2013, 13:434 Page 8 of 10
http://www.biomedcentral.com/1471-2407/13/434Patients up to 35 years of age were not more likely to
die from breast cancer than patients 36–69 years of age.
This could be due to our small number of cases at this
age (only 47 women were younger than 35 years of age).
These patients are unlikely to die from other causes
when diagnosed with breast cancer [37,38]. Women with
more advanced stages at diagnosis or recurrent disease
are also more likely to die of breast cancer [23,37,38]. It
is still debated whether younger age at diagnosis is an
independent prognostic factor for shorter survival or if
younger patients have tumors with worse biological fea-
tures [37,39].
Our study has some limitations. First, the possibility of
having wrongly classified a woman as being dead or alive
exists, due to possible errors in the Mortality Informa-
tion System. Three variables (patients’ names, mothers’
names and date of birth) were used in the record linkage
to minimize this bias. Also, fathers’ names and patients’
addresses were used to confirm the pair as a true one.
The medical records for a small sample of patients (70
cases, 0.08%) were checked. Only one patient was identi-
fied as having moved to another state, and since infor-
mation on life status could be wrong, she was excluded
from the study. Second, since high-quality data were
only available in surgical treatment and neoadjuvant
therapies, we chose not to include these variables in the
multivariate Cox model, to avoid bias. The inclusion of
patients who underwent neoadjuvant systemic therapies
is unlikely to have affected our results; those patients
had more advanced tumors at diagnosis and thus would
very likely have undergone chemotherapy after surgery.
Also, information on socioeconomic status, such as fam-
ily income and educational level, were not available.
Paim et al. [11] reported that having a private insurance
is correlated with family income; thus, in our study, not
having a private insurance was considered a surrogate
for lower socioeconomic status.
On the other hand, our study also has strengths.
Selecting patients from pathology reports has the advan-
tage of providing good-quality data regarding stage,
histologic tumor grade, and type. The information on
histologic grade was missing in only 11 patients, either
because the invasive component was too small (mic-
roinvasive tumor) or because the patient underwent
neoadjuvant systemic therapy and the tumor sample
prior to the systemic treatment was insufficient to assess
histological grade. Even though we have limited informa-
tion on treatment due to the origin of our data, this
study brings insight into recent survival of women with
operable breast cancer at a tertiary health facility that
treats mostly low-income patients.
Different methods are used for survival analysis. Over-
all mortality, cause-specific mortality, and relative sur-
vival have all been used as endpoints [23,37,40]. Theproblem with the use of cause-specific mortality is the
difficulty, in some cases, in attributing a death to breast
cancer or its treatment [23,41]. For instance, some
common sites for metastases of breast tumors can be
reported as the primary site in death certificates, such as
lung, bone, liver, and brain [41].
Cancer-specific survival depends on the data quality of
death certificates, as well as in appropriate coding of
reported causes of death. In Brazil, data quality has im-
proved over the years [22], but still there are deaths of
unknown causes or without medical assistance (2.8% of
our cases). Moreover, even when death causes are cited
in the death certificate, sometimes it is difficult to attri-
bute a death to breast cancer or its treatment [17,23]. In
our study, 25 deaths (9.22% of total of deaths) were not
initially considered to be from breast cancer in the Mor-
tality Information System. The cause reported by this
system is the one considered in national mortality statis-
tics; thus, wrongly assigning a cause could influence
these indexes. On the contrary, all-cause mortality could
result in underestimation of breast cancer survival
[23,40]. Since we needed comparability with Brazilian
cohorts, breast-cancer specific survival was used.
Different populations are subject to innumerous differ-
ences in life expectancy, life styles, and access to health
care that could affect their survival, both from breast can-
cer and from other causes [4,6,9,23,27]. Trying to make
comparisons among populations can help highlight these
differences and guide local policies towards a more effect-
ive approach to breast cancer care, especially through
earlier diagnosis and treatment of the disease [1,8,10,33].
For instance, in spite of not having addressed patients’
comorbidities, this study suggests that policymakers
should pay attention to women older than 70 years; with
screening, it is possible that they will be diagnosed with
earlier tumors. Since age is the most important risk factor
for breast cancer, and the Brazilian population is aging
[11], this should be taken into account.
Conclusions
In our study, 5-year breast cancer-specific survival was
comparable to the one estimated for other Brazilian
cohorts. Comparisons with estimates for high-income
countries showed mixed results, which may be due to
differences in the socioeconomic, demographic and
health characteristics of the population subgroups
analysed in each study. Also, patients treated by the SUS
had a shorter survival rate than those treated through
the private system, mostly due to higher initial stage of
the disease. Patients older than 70 years had shorter sur-
vival time in comparison with patients 36–69 years of
age. After reassigning the cause of death reported in the
death certificate, more patients were considered to have
died from breast cancer than when using only the basic
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of the possible pitfalls of national cancer mortality
statistics.
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